Raze Therapeutics

Raze Therapeutics is a biotechnology company focused on developing innovative therapies targeting cancer and other diseases by manipulating cellular metabolism. Raze Therapeutics specializes in developing cancer therapies that target metabolic dependencies of tumors. Founded in Cambridge, US, the company has not undergone significant pivots and operates independently. The company raised USD 19.

80 mn in Series A funding from investors including Atlas Venture and Novartis on October 14, 2014. This funding brought the total amount raised to USD 19. 80 mn, establishing a company valuation of USD 29. 19 mn.

Raze Therapeutics focuses on the design and development of novel therapeutics aimed at metabolic pathways in cancer cells. Their primary products involve targeted therapies designed to exploit metabolic vulnerabilities in tumors, which can enhance the efficacy of existing treatments and improve patient outcomes. The company serves oncology-focused healthcare providers and research institutions globally, aiming to provide innovative solutions tailored to specific cancer types. The revenue model for Raze Therapeutics is centered around partnerships and collaborations with pharmaceutical companies for developing their therapeutics.

Revenue is generated through milestone payments and potential royalties on product sales once their therapies reach the market. These financial arrangements are structured to sustain ongoing research and development efforts. Raze Therapeutics plans to expand its product offerings by developing new therapeutics targeting additional metabolic pathways by the end of 2025. The recent Series A funding of USD 19.

80 mn will be utilized to accelerate research and development initiatives and support clinical trials for their lead candidates. The company is also exploring market expansion opportunities in Europe and Asia, aiming to establish partnerships with local healthcare providers and research institutions by 2026.